Press

2017-09-25 News

Intervacc has presented results from clinical trials at a scientific meeting on strangles

"Getting to grips with strangles" is a regularly recurring international scientific meeting on research on strangles a highly contagious horse disease. At the meeting held in Montanan, USA, in September 2017, Intervacc's CEO, Jan-Ingmar Flock, ... Read more

2017-08-01 News

Intervacc has presented results from clinical trials at WEAS 2017

The WEAS (World Equine Airway Symposium) is a regularly recurring international ... Read more

2017-03-01 News

Intervacc now on Introduce.se

Starting today March 1st, 2017 Intervacc becomes overviewed by Introduce.se

Intervacc conducts share issue, directed to both previous and new investors

Intervacc is now carrying out a new share issue of 3,624,518 shares with preferential rights for the shareholders. This issue provides the company with approximately SEK 8.3 million. Shareholders of record date October 13, ... Read more

2016-09-21 News

Strangvac® clinical trials confirm expected efficacy

A series of trials have been conducted at the Animal Health Trust, Newmarket, England. The trials were aimed to measure the safety, immunogenicity, efficacy and DIVA (differentiates infected from vaccinated animals) ... Read more

2015-10-28 News

Intervacc signs agreement for optimization of manufacturing

Intervacc is pleased to announce that an agreement has now been signed with PX´Therapeutics, Grenoble, France, for process optimization of Strangvac. PX´Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the ... Read more